10h agoThe FlyBULLISH 64Analyst
Archived explainer. For the current picture see today's BLTE page.
Why Is BELITE BIO INC ADR (BLTE) Stock Down Today?
By the Top Tier Newswire AI Desk · November 13, 2026 at 9:54 AM ET · reviewed against 8 wire stories
BELITE BIO INC ADR (BLTE) is down -7.59% in the latest session. Our newswire has captured 8 stories on BLTE across 6 sources in the last 36 hours, with AI sentiment reading mixed (avg 55/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Belite Bio (BLTE) shares fell 7.59% to $157.06. The primary driver was the release of third-quarter financial results, which showed a non-GAAP EPS of -$0.60, beating estimates by $0.17 despite the company remaining unprofitable.
What Happened
Belite Bio reported unaudited third-quarter 2026 financial results on November 12, 2026. The company posted a non-GAAP EPS of -$0.60, which exceeded the consensus estimate of -$0.77. As of September 30, 2026, the company held $271.3 million in cash and cash equivalents. Management outlined regulatory timing and commercial plans for its Stargardt drug during the earnings call. The New Drug Application for tinlarebant in Stargardt disease type 1 was granted priority review by the U.S. Food and Drug Administration in August 2026.
Following the report, Leerink raised its price target to $215 from $185. StoneX reiterated a Buy rating with a $217 price target. The stock had previously been uplisted to the Nasdaq Global Select Market.
What The Data Shows
The stock opened at $172.80, a 1.7% gap from the prior close of $169.96. It reached a session high of $174.25 at 8:30 AM ET before declining to a session low of $157.06 at 9:50 AM ET. Volume was 0.0M shares, which is 0.2x the 3-month daily average. The company has a market cap of $6.3B and is unprofitable with a trailing twelve-month EPS of -2.74. The 52-week range is $105.88 to $200.00. Over the last eight sessions, the stock moved 11.7% from $152.17 to $169.96.
Recent insider activity includes three sales totaling $32.0M in the last 90 days. Chief Medical Officer Scholl Hendrik Peter sold on October 1, 2026. Chief Financial Officer Chuang Hao-Yuan and Chief Executive Officer Lin Yu-Hsin both sold on September 4, 2026. The stock printed four fresh 52-week lows on November 13, 2026.
What To Watch
Investors will monitor the company's progress with the FDA priority review for tinlarebant. The upcoming PDUFA target date for the Stargardt disease drug remains a key catalyst for the stock's valuation.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
BLTE by the numbers
Last: $157.06Session: -7.59%7 sessions: +6.72%Coverage: 8 stories / 6 sourcesAI sentiment: 55/100 (mixed)Mkt cap: $6.3B52w: $105.88 to $200.00
The headlines behind the move
12h agoInvesting.com Analyst RatingsBULLISH 63Analyst
StoneX reiterates Buy rating on Belite Bio stock, $217 target
StoneX reiterates Buy rating on Belite Bio stock, $217 target
18h agoThe Motley FoolBULLISH 56Earnings
Belite Bio (BLTE) Q3 2026 Earnings Call Transcript
Management outlined regulatory timing and commercial plans for its Stargardt drug.
1d agoSeeking AlphaNEUTRAL 50Earnings
Belite Bio, Inc (BLTE) Q3 2026 Earnings Call Transcript
Belite Bio, Inc (BLTE) Q3 2026 Earnings Call November 12, 2026 4:30 PM ESTCompany ParticipantsJulie FallonYu-Hsin Lin - Chairman of the Board of Directors...
1d agoGuruFocusBULLISH 58Earnings
Belite Bio (BLTE) Q3 Earnings Beat Estimates Amid Loss-Making Status
1d agoBusiness InsiderBULLISH 63Earnings
Belite Bio Non-GAAP EPS of -$0.60 beats by $0.17
Belite Bio press release (BLTE): Q3 Non-GAAP EPS of -$0.60 beats by $0.17.As of September 30, 2026, the Company had $271.3 million in cash and cash...
1d agoThe FlyBEARISH 22Earnings
Belite Bio reports Q3 non-GAAP EPS (26c), consensus (77c)
1d agoBusiness InsiderBULLISH 64Earnings
Belite Bio Reports Unaudited Third Quarter 2026 Financial Results and Provides a Corporate Update
New Drug Application (NDA) for tinlarebant in Stargardt disease type 1 (STGD1) granted priority review by the U.S. Food and Drug Administration (FDA) in August 2026 with Prescription Drug User Fee Act (PDUFA) target...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on BLTE: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier BLTE move explainers: 2026-11-13 · 2026-11-12 · 2026-09-08 · 2026-09-04